Discovery by researchers from Concordia and Berkeley could lead to the synthetic manufacturing of painkillers and other drugs
Moonshiners and home-brewers have long used yeast to convert sugar into alcohol. New research shows that those methods could also be adapted for something with more significant ramifications: the production of drugs including opiates, antibiotics, and anti-cancer therapeutics.
According to new studies by researchers from Concordia University in Montreal and the University of California, Berkeley, yeast can be engineered to convert sugar to alkaloids — plant-derived compounds such as codeine and morphine, naturally produced in the opium poppy.
Collaborating on synthesis
Thanks to research by teams led by Vincent Martin at Concordia and John Dueber at UC Berkeley, the key steps needed to make yeast able to produce alkaloids from inexpensive sugar have been identified.
In a new study published in Nature Chemical Biology the researchers were able to synthesize reticuline, a compound from which most alkaloids derive, including the opiates morphine and codeine as well as many other potential new drugs.
“Getting to reticuline is critical for the process to be economically viable because from there, most of the molecular steps that produce codeine and morphine have been identified in yeast,” says Martin, who is a professor of microbial genomics and engineering at Concordia. “We can explore many different paths to other potential drugs, not just opiates.”
The proof is in the yeast
In a related study published in PLoS ONE, Martin and his group also engineered yeast for the production of thebaine, a precursor of codeine, morphine and oxycodone, from reticuline. This work further proves that yeast could revolutionize the way complex compounds like alkaloids will be produced in the future.
Demonstrating that yeast can make valuable known pharmaceuticals is only the beginning. The ultimate goal is to create new complex compounds with therapeutic effects that aren’t naturally produced in high enough volumes to meet demand.
Together, these new studies describe the almost complete process to make opiates from sugar.
Red flag for regulators
Prior to these studies, opiates could only be made from expensive starting molecules, most of which are currently regulated as controlled substances and therefore not readily available without strict permits from governmental agencies.
Martin and Dueber are conscious of the serious implications of their discovery: it allows for the potential of “home-brewing” opioids. They are calling for regulators and law enforcement officials to pay close attention.
The Latest on: Synthetic drug manufacturing
via Google News
The Latest on: Synthetic drug manufacturing
- New Coalition Dedicated To Fostering American Synthetic Biology Manufacturing Launched Todayon April 14, 2021 at 6:44 am
Its synthetic biology platform surpasses the limits of conventional drug discovery and manufacturing through a novel approach to whole-cell engineering — reconstructing complex molecules in ...
- Meet The Company Reprogramming The Future Of Synthetic Biologyon April 14, 2021 at 6:00 am
By combining the power of synthetic biology with stem cells, the company can create new cell therapies and provide human cells for research, drug discovery, and manufacturing. Validation From Top ...
- Biopharmaceutical Manufacturers Tighten their Grip on Protein A Resin Marketon April 8, 2021 at 4:32 am
Growing investments in synthetic biology is accelerating adoption of protein engineered products in order to manufacture protein infused drugs and formulations ... register positive year-on-year ...
- AcornMed Selects Twist Bioscience Technology to Power Next Generation Precision Medicine Testson April 7, 2021 at 7:30 pm
“Twist Bioscience’s proprietary DNA manufacturing ... including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development.
- Scientific Challenges and Solutions for Cultured Meat Manufacturingon April 7, 2021 at 8:10 am
The rising environmental cost of cattle meat production, emergence of multi-drug resistant bacteria from ... cultivated meat, or synthetic meat. In 2013, Mark Post, PhD, professor at Maastricht ...
- Bacteriophage to the Future: Insights from the 3rd Bacteriophage Therapy Summiton April 7, 2021 at 8:08 am
These challenges range from a developing regulatory landscape and the design of clinical trials to the up-scaling of manufacturing ... hundreds of drug developers, academics, and clinical ...
- More expansion for Piramal as Indian CDMO gobbles up local peptide manufacturer for $105Mon April 1, 2021 at 1:52 pm
develops and manufactures synthetic peptide ingredients from its two main sites nearby. The company has a manufacturing site in suburban Turbhe that's certified by the U.S. Food and Drug ...
- Piramal Pharma Ltd. To Acquire 100% Stake in Hemmo Pharmaceuticals, a Leading Indian Manufacturer of Peptide APIson March 31, 2021 at 9:24 pm
Hemmo is one of the few pure-play synthetic peptide API manufacturers in the ... Organization (CDMO), offering end-to-end development and manufacturing solutions across the drug life cycle. We serve ...
- Piramal Pharma Ltd. To Acquire 100% Stake in Hemmo Pharmaceuticals, a Leading Indian Manufacturer of Peptide APIson March 31, 2021 at 12:05 pm
Hemmo is one of India's largest manufacturers of synthetic peptides with a legacy ... "During the past decade, peptide drugs have seen increased use in oncology, treatment of diabetes and obesity.
- High Potency Active Pharmaceutical Ingredient (HPAPI) Market: Patent Expiry of Blockbuster Drugs Propel Global Market Growthon March 31, 2021 at 8:51 am
Numerous drugs consisting synthetic HPAPI are slated to go off patent in the near future. This would unlock a huge market opportunity for generic drug manufacturers, resulting in augmented demand ...
via Bing News